Home drugs Lynparza (Olaparib)

Lynparza (Olaparib)

This page contains brief information about olaparib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Olaparib is approved to treat:

  • Breast cancer that has metastasized (spread to other parts of the body). It is used in patients with certain mutations in the BRCA1 or BRCA2 genes who have HER2-negative cancer that has been treated with chemotherapy given before or after surgery or for metastatic disease.
  • Ovarian cancer that is advanced. It is used in patients with certain mutations in the BRCA1 or BRCA2 genes who have already been treated with at least three other types of chemotherapy.
  • Ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is used as maintenance therapy in patients with recurrent disease who are having a complete or partial response to platinum chemotherapy.

Olaparib is also being studied in the treatment of other types of cancer.

More About Olaparib

Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.

MedlinePlus Information on Olaparib – A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.